1. Home
  2. ACAD
  3. ACAD News

Latest ACADIA Pharmaceuticals Inc. (ACAD) News on June 2, 2025

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
ACAD

Business Wire

4 days ago

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
ACAD

Business Wire

6 days ago

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

ACAD

MT Newswires

12 days ago

Deutsche Bank Upgrades ACADIA Pharmaceuticals to Buy From Hold, Price Target is $20

ACAD

Argus Research

13 days ago

ACAD: Raising target price to $23.00

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

13 days ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday
ACAD

Insider Monkey

13 days ago

Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday

Biotech Alert: Searches spiking for these stocks today
ACAD

TipRanks

13 days ago

Biotech Alert: Searches spiking for these stocks today

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93
ACAD

Investor's Business Daily

14 days ago

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93

Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer
ACAD

TipRanks

16 days ago

Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer

Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital
ACAD

TipRanks

16 days ago

Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital

ACAD

MT Newswires

17 days ago

Acadia Wins Nuplazid Patent Case in Delaware Court; Shares Surge

ACAD

Argus Research

20 days ago

ACAD: Raising target price to $18.00

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)
ACAD

Zacks

24 days ago

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)

Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD

Zacks

25 days ago

Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

ACAD

Thomson Reuters StreetEvents

25 days ago

Q1 2025 ACADIA Pharmaceuticals Inc Earnings Call

ACAD

MT Newswires

25 days ago

Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $20 From $22, Maintains Hold Rating

ACADIA Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
ACAD

GuruFocus.com

25 days ago

ACADIA Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

ACAD

Associated Press Finance

a month ago

Acadia: Q1 Earnings Snapshot

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
ACAD

Business Wire

a month ago

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

ACAD

Argus Research

a month ago

ACAD: What does Argus have to say about ACAD?

US High Growth Tech Stocks To Watch In Your Portfolio
ACAD

Simply Wall St.

a month ago

US High Growth Tech Stocks To Watch In Your Portfolio

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference
ACAD

Business Wire

a month ago

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
ACAD

Zacks

a month ago

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

ACAD

MT Newswires

a month ago

UBS Adjusts ACADIA Pharmaceuticals Price Target to $22 From $25, Maintains Buy Rating

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
ACAD

Business Wire

a month ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

ACAD

Argus Research

a month ago

ACAD: Lowering target price to $15.00

ACAD

MT Newswires

2 months ago

BofA Adjusts Price Target on ACADIA Pharmaceuticals to $18 From $19, Keeps Neutral Rating

ACAD

Argus Research

2 months ago

ACAD: Raising target price to $16.00

Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?
ACAD

Simply Wall St.

2 months ago

Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

2 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ACAD

Argus Research

2 months ago

ACAD: Lowering target price to $15.00

ACAD

Argus Research

2 months ago

ACAD: Lowering target price to $17.00

ACAD

Argus Research

2 months ago

ACAD: What does Argus have to say about ACAD?

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts
ACAD

Insider Monkey

2 months ago

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts

Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now?
ACAD

Insider Monkey

3 months ago

Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now?

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

3 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
ACAD

Business Wire

3 months ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
ACAD

Business Wire

3 months ago

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)
ACAD

Zacks

3 months ago

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)

ACAD

Argus Research

3 months ago

ACAD: Lowering target price to $19.00

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)
ACAD

Zacks

3 months ago

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)

ACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
ACAD

Simply Wall St.

3 months ago

ACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
ACAD

Business Wire

3 months ago

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
ACAD

GuruFocus.com

3 months ago

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
ACAD

Simply Wall St.

3 months ago

Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
ACAD

Business Wire

3 months ago

Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ...
ACAD

GuruFocus.com

3 months ago

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ...

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
ACAD

Zacks

3 months ago

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
ACAD

Zacks

3 months ago

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates

ACAD

Associated Press Finance

3 months ago

Acadia: Q4 Earnings Snapshot

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
ACAD

Business Wire

3 months ago

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

ACAD

Argus Research

3 months ago

ACAD: Lowering target price to $20.00

ACAD

Argus Research

3 months ago

ACAD: Raising target price to $21.00

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

4 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?
ACAD

Zacks

4 months ago

Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
ACAD

Business Wire

4 months ago

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

ACAD

MT Newswires

4 months ago

Deutsche Bank Initiates Coverage on ACADIA Pharmaceuticals With Hold Rating, $22 Price Target

High Growth Tech Stocks To Watch In February 2025
ACAD

Simply Wall St.

4 months ago

High Growth Tech Stocks To Watch In February 2025

ACAD

Argus Research

4 months ago

ACAD: Raising target price to $20.00

ACAD

Argus Research

4 months ago

ACAD: What does Argus have to say about ACAD?

ACAD

Argus Research

4 months ago

ACAD: Raising target price to $19.00

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

5 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ACAD

Argus Research

5 months ago

ACAD: What does Argus have to say about ACAD?

Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025
ACAD

GuruFocus.com

5 months ago

Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025

ACAD

MT Newswires

5 months ago

Acadia Pharmaceuticals Seeks EU Marketing Approval for Rett Syndrome Treatment

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
ACAD

Business Wire

5 months ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
ACAD

Business Wire

5 months ago

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20?
ACAD

Insider Monkey

5 months ago

Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20?

Further weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) drops 5.2% this week, taking five-year losses to 61%
ACAD

Simply Wall St.

5 months ago

Further weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) drops 5.2% this week, taking five-year losses to 61%

ACAD

MT Newswires

5 months ago

Guggenheim Downgrades ACADIA Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $20 From $23

Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing
ACAD

Insider Monkey

5 months ago

Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing

ACAD

MT Newswires

5 months ago

Update: Acadia Pharmaceuticals to Replace Independent Bank in S&P SmallCap 600; Acadia Shares Rise

Acadia Pharmaceuticals Set to Join S&P SmallCap 600
ACAD

PR Newswire

5 months ago

Acadia Pharmaceuticals Set to Join S&P SmallCap 600

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
ACAD

Business Wire

5 months ago

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

6 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In December 2024
ACAD

Simply Wall St.

6 months ago

High Growth Tech Stocks To Watch In December 2024

ACAD

MT Newswires

6 months ago

ACADIA Pharmaceuticals Closes Sale of Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
ACAD

Business Wire

6 months ago

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
ACAD

Business Wire

6 months ago

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
ACAD

Zacks

6 months ago

Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term

Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
ACAD

Zacks

6 months ago

Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options

ACAD Signs License Deal With Saniona for Rights to Neurology Drug
ACAD

Zacks

6 months ago

ACAD Signs License Deal With Saniona for Rights to Neurology Drug

Acadia signs agreement with Saniona to commercialise SAN711
ACAD

Pharmaceutical Technology

6 months ago

Acadia signs agreement with Saniona to commercialise SAN711

ACAD

MT Newswires

6 months ago

Acadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
ACAD

Business Wire

6 months ago

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
ACAD

Business Wire

6 months ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

7 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks to Watch in November 2024
ACAD

Simply Wall St.

7 months ago

High Growth Tech Stocks to Watch in November 2024

Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
ACAD

Zacks

7 months ago

Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock

ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next
ACAD

Simply Wall St.

7 months ago

ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next

ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
ACAD

Simply Wall St.

7 months ago

ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations

ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...
ACAD

GuruFocus.com

7 months ago

ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates
ACAD

Zacks

7 months ago

Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates

ACAD

Associated Press Finance

7 months ago

Acadia: Q3 Earnings Snapshot

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
ACAD

Business Wire

7 months ago

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
ACAD

Business Wire

7 months ago

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024
ACAD

Insider Monkey

7 months ago

ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
ACAD

Business Wire

8 months ago

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Health Canada approves Acadia’s DAYBUE for Rett syndrome
ACAD

Pharmaceutical Technology

8 months ago

Health Canada approves Acadia’s DAYBUE for Rett syndrome

ACAD

MT Newswires

8 months ago

ACADIA Pharmaceuticals' Rett Syndrome Treatment Gets Health Canada Approval

Share on Social Networks: